Nbb - If the time in the the trial was correct at the 23 Feb broker meeting then ZEN3694 will have been in use in that test patient now for 8 or 9 months now if he is still with us. About 7 months was the time stated at that meeting. If my understanding was correct, once these patients no longer respond to Enzalutimide or Aberaterone, (pardon the spelling) their longevity is dramatically reduced. Having a patient (or more) continuing to respond to ZEN3694 has to be a very good selling point for Zenith management.

It would be nice if the Zenith shareholders could put some new toys in their toy box before the end of the summer.

tada